Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04399252
Recruitment Status : Not yet recruiting
First Posted : May 22, 2020
Last Update Posted : May 22, 2020
Sponsor:
Information provided by (Responsible Party):
Duke University

Brief Summary:
The purpose of this study is to evaluate the effect of the probiotic Lactobacillus rhamnosus GG (LGG) and the effect of COVID-19 on the microbiome (the microorganisms that live in and on the human body) in exposed household contacts of COVID-19. This is a randomized, double-blind, placebo-controlled study, meaning subjects will be randomly assigned to receive LGG or a placebo (an inactive substance given in the same form as the active substance) and will not know which product they are receiving. Subjects will participate in the study for around 60 days. All subjects must refrain from taking any other probiotics while on study. All subjects must have access to e-mail and the internet to complete study questionnaires. Participation in this study entails taking LGG/placebo for 28 days, responding to questionnaires, and providing stool and nasal swab samples.

Condition or disease Intervention/treatment Phase
Microbiome Dietary Supplement: Lactobaciltus rhamnosus GG Dietary Supplement: Lactobaciltus rhamnosus GG Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: A Randomized Trial of the Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19
Estimated Study Start Date : May 25, 2020
Estimated Primary Completion Date : May 25, 2022
Estimated Study Completion Date : May 25, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LGG Arm
Participants in this arm will be given LGG for 28 days.
Dietary Supplement: Lactobaciltus rhamnosus GG
Participants will take 2 capsules per day of either LGG or placebo.

Placebo Comparator: Placebo
Participants in this arm will be given a placebo for 28 days.
Dietary Supplement: Lactobaciltus rhamnosus GG Placebo
Participants will take 2 capsules per day of LGG placebo




Primary Outcome Measures :
  1. Change in Shannon Diversity [ Time Frame: Baseline, Day 7, and Day 28 ]

Secondary Outcome Measures :
  1. Change in Shannon Diversity in patients that develop COVID-19 [ Time Frame: Baseline, Day 7, and Day 28 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age >=1 year (as children <1 year may not be able to take oral probiotics)
  • Household contact of someone diagnosed with COVID-19
  • Willingness to stop taking other probiotics or to not take any other probiotic while on LGG/placebo (taking a probiotic at the time of screening will not be considered a reason for exclusion. However, subjects will be asked to stop taking their probiotic if they enroll on the study).
  • Access to e-mail/internet to complete electronic consent via REDCap

Exclusion Criteria:

  • Symptoms of COVID-19 at enrollment, including:

    • Fever
    • Respiratory symptoms
    • GI symptoms
    • Anosmia
    • Ageusia ->7 days since original patient associated with household contact was diagnosed with COVID-19
  • Taking hydroxychloroquine or remdesevir for any reason (as this would have the potential to decrease the expected rate of COVID-19 in this population and affect our power and sample size calculations)
  • Enrolled in a COVID-19 prophylaxis study (as this would have the potential to decrease the expected rate of COVID-19 in this population and affect our power and sample size calculations)
  • Any medical condition that would prevent taking oral probiotics or increase risks associated with probiotics including but not limited to:

    • Inability to swallow/aspiration risk and no other methods of delivery (e.g., no G/J tube)
    • Increased infection risk due to immunosuppression due to:

      • Chronic immunosuppressive medication
      • Prior organ or hematopoietic stem cell transplant
      • Known neutropenia (ANC <500 cells/ul)
      • HIV and CD4 <200 cells/ul
    • Increased infection risk due to endovascular due to:

      • Rheumatic heart disease
      • Congenital heart defect,
      • Mechanical heart valves
      • Endocarditis
      • Endovascular grafts
      • Permanent endovascular devices such as permanent (not short-term) hemodialysis catheters, pacemakers, or defibrillators
    • Increased infection risk due to mucosal gastrointestinal due to:

      • Gastroesophageal or intestinal injury, including active bleeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04399252


Contacts
Layout table for location contacts
Contact: Lauren Bohannon 919-668-2369 lauren.bohannon@duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Contact: Lauren Bohannon    919-668-2369    lauren.bohannon@duke.edu   
Sponsors and Collaborators
Duke University
Investigators
Layout table for investigator information
Principal Investigator: Anthony Sung, MD Duke University
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT04399252    
Other Study ID Numbers: Pro00105674
First Posted: May 22, 2020    Key Record Dates
Last Update Posted: May 22, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Duke University:
COVID-19
Lactobacillus rhmnosus GG